Multisystem Impact of Metabolic Dysfunction-associated Steatotic Liver Disease in Clinical Practice
Year: 2026
Type: article
Abstract: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and is closely linked to obesity, type 2 diabetes, dyslipidemia, and arterial hypertension. The 2023 change in nomenclature placed cardiometabolic dysfunction at the center of the diagnosis and reinforced the understanding of the condition as a systemic disorder, whose consequences extend well beyond the liver. This review aimed to analyze the multisystem impact of MASLD and to discuss its implications for the daily practice of the clinician, including risk stratification, follow-up, and treatment. This is a narrative literature review, guided by a structured question based on the PICo strategy and directed at studies on the hepatic and extrahepatic outcomes of adults with MASLD. The evidence shows that the disease is associated with a higher risk of fatal and nonfatal cardiovascular events, heart failure, incident type 2 diabetes, chronic kidney disease, and extrahepatic cancers, with risk increasing according to the severity of liver disease, especially the stage of fibrosis. Cardiovascular disease and extrahepatic cancers account for a large share of the excess mortality, while fibrosis remains the main determinant of liver outcomes. Noninvasive assessment of fibrosis, starting with FIB-4 and followed by elastography when indicated, allows the identification of patients at higher risk in primary care. Lifestyle intervention remains the basis of treatment, and recent trials with resmetirom and semaglutide have expanded the pharmacological options for steatohepatitis with significant fibrosis. It is concluded that MASLD should be approached as a multisystem cardiometabolic disease, requiring integrated management of liver, cardiovascular, renal, and metabolic risk by the clinician.
Source: Artefactum
Authors: Lucileia Mazuqueli Marques, Mirella Cristina Mazuqueli Marques, Dianah Dantas Pulvirenti, Bruna Gonçalves Manzoni, Edna Pereira da Silva, Maria Júlia Daniel Peixoto, Ana Carolina Fontana Bolsoni, Guilherme Almeida dos Reis Santos, Guilherme Augusto Ferrari Pavoni, Luiz Carlos Borsanelli Júnior, Flávio Renan Ramiro, Beatriz Camilly Fernandes, Rodolfo de Oliveira Medeiros
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Keywords: non-alcoholic fatty liver disease, cardiometabolic dysfunction, cardiovascular risk, heart failure, type 2 diabetes, chronic kidney disease, extrahepatic cancer, liver fibrosis, noninvasive fibrosis assessment, FIB-4, elastography, lifestyle intervention, resmetirom, semaglutide, steatohepatitis, risk stratification, primary care
Open Access status: diamond
OpenAlex ID: W7236571022
